Is the @entity112 skin test inhibited by XXXX ?

@entity1 @entity229 @entity56 @entity112
BACKGROUND: A clinical trial was carried out to determine whether therapeutic doses of @entity229 could inhibit the response to the @entity112 skin test. METHODS: Forty-five male and female asthmatic and @entity56 @entity1 participated in the study, their ages ranged from 6-14 years old (16 @entity1 and 29 @entity1 ). The clinical trial was random, double-blind, and placebo-controlled. METHODS: Three treatment groups were formed and @entity1 were assigned randomly to them. Groups A and B received @entity229 at 0.5 and 1 mg/kg/day, respectively, whereas group C received a placebo (p.o.). All treatments lasted for 10 days. The @entity112 test was applied on the first, fifth and tenth days of treatment, and the size of the wheal and the extension of the flare were evaluated 5 min after the application of the test. The statistical tool used was ANOVA, since the study sought to see the difference among the treatment groups, after including 45 @entity1 in three groups of 15 @entity1 each. RESULTS: No significant statistical difference was observed among the groups using an ANOVA test. CONCLUSIONS: It was concluded that the response to the @entity112 test was not modified by a 10-day treatment with @entity229 at doses of 0.5 mg/kg/day and 1 mg/kg/day.
